Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
CSBR Stock Chart & Stats
$6.64
-$0.91(-8.67%)
At close: 4:00 PM EST
$6.64
-$0.91(-8.67%)
Day’s Range― - ―
52-Week Range$5.59 - $11.06
Previous CloseN/A
Volume27.06K
Average Volume (3M)17.98K
Market Cap
$82.69M
Enterprise Value$79.45M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$5.27M
Price to Earnings (P/E)35.8
Beta0.43
Next Earnings
Mar 17, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding13,886,326
10 Day Avg. Volume35,034
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)25.89
Price to Sales (P/S)1.72
P/FCF Ratio13.96
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.36
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda20.56
Forecast
1Y Price Target
$12.00Price Target Upside80.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)$58.53M
Bulls Say, Bears Say
Bulls Say
Proprietary TumorGraft & RadiolabelingChampions' unique TumorGraft/radiolabeling capabilities create high technical barriers and differentiated preclinical services. These specialized platforms foster long-term partnerships with pharma customers, support repeat revenue, and enhance pricing power in oncology drug development over multiple years.
Improving Gross Margins And ProfitabilitySustained margin improvement to the low-50s reflects operational efficiencies and higher-value engagements. Higher gross margins strengthen the company's ability to convert incremental revenue into durable operating profit, supporting reinvestment and resilience through biotech cycle volatility.
Positive Operating And Free Cash Flow (TTM)Trailing-twelve-month positive operating and free cash flow indicate the business can generate internal funds to support growth and strategic investments. Consistent cash generation reduces reliance on equity dilution and provides a runway to scale the data platform and commercial efforts.
Bears Say
Elevated Leverage And Thin EquityDebt exceeding equity leaves limited balance-sheet cushion for a biotech firm where revenue and project timings can fluctuate. Elevated leverage raises refinancing risk and constrains flexibility to fund R&D or absorb setbacks without increasing financial cost or raising capital.
Quarterly Cash Flow VariabilityQuarterly net cash outflows tied to deferred revenue shifts highlight cash conversion volatility. Such swings can strain near-term liquidity and complicate planning for investments and debt service, requiring conservative cash management as the company scales its data platform and commercial team.
Rising Operating Expenses From InvestmentsHigher operating spend to build the data platform and commercial footprint can pressure margins if revenue growth lags. Sustained elevated OpEx increases the execution burden: the company must convert customer interest into recurring, higher-margin contracts to justify the investment and avoid recurring cash deficits.
Champions Oncology News
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $5.59 and its highest was $11.06 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $82.69M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Mar 17, 2026 which is in 15 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Dec 15, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0 by $0.06.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Undervalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate is 0.09.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,886,326 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.06 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -13.718%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (80.72% Upside)
$12.00 (80.72% Upside)
Blogger Sentiment
Bullish
CSBR Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.39%
12-Months-Change
Fundamentals
Return on Equity
102.74%
Trailing 12-Months
Asset Growth
19.50%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology (CSBR) is a biotechnology company that specializes in personalized medicine, particularly in the field of oncology. The company develops advanced technology platforms, including its proprietary TumorGraft® technology, which allows for the creation of patient-derived tumor models for use in drug development and treatment selection. By providing solutions that enhance the understanding of cancer biology and treatment responses, Champions Oncology serves pharmaceutical companies, academic institutions, and healthcare providers globally.
CSBR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong year-over-year revenue growth and improved gross margins, indicating a positive trajectory for Champions Oncology. Strategic investments in radiolabeling and the data platform are expected to drive long-term growth. However, increased operating expenses and cash flow challenges present areas of concern. Overall, the company's positive financial performance and strategic direction suggest a favorable outlook.View all CSBR earnings summariesCSBR Stock 12 Month Forecast
Average Price Target
$12.00
▲(80.72% Upside)
Technical Analysis
Cassava Sciences
―
Protalix
―
Atossa Therapeutics
―
Anixa Biosciences
―
Actuate Therapeutics, Inc.
―
Ownership Overview
14.82% Insiders
3.06% Mutual Funds
3.09% Other Institutional Investors
76.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---